FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099494304> ?p ?o ?g. }

• W2099494304 endingPage "357" @default.
• W2099494304 startingPage "346" @default.
• W2099494304 abstract "Dermatologic corticosteroid products produce skin blanching that is related to clinical potency and dose. (For application of the vasoconstrictor assay to bioavailability and bioequivalence assessment, dose is defined in terms of duration of treatment exposure [dose duration], so the terms dose and dose duration have been used interchangeably). The vasoconstrictor assay is the method of choice to assess dermatologic corticosteroid products bioequivalence if dose-response is validated. This article examines dose-response validation to meet objectives of US Food and Drug Administration (FDA) bioequivalence guidance for dermatologic corticosteroid products.An exploratory dose-response study was conducted to determine applicability of the empirical maximum effect (Emax) model to the individual subject and population dose-response relationships of six dermatologic corticosteroid product creams that varied from the most to the least potent classes. Products were applied to the skin of 10 healthy subjects in each of two dosing periods for dose durations of 0.5, 1, 2, and 6 hours. Skin blanching was measured by reflectance colorimeter through 24 hours after application. Area under the effect curve (AUEC) was determined for each dose duration. An Emax model was fitted to the AUEC versus dose duration data. A similar analysis was conducted for a bioequivalence study on two formulations of a dermatologic corticosteroid product in 40 healthy subjects.In the exploratory study, the number of individual subject data sets for which the Emax model provided an acceptable fit generally increased with the potency of the dermatologic corticosteroid product. On the basis of population modeling, dose-response data of all products, except the lowest potency cream, were adequately described by the Emax model. Values for population ED50 (the dose duration required to achieve 50% of the fitted AUECmax value) decreased with increase in dermatologic corticosteroid product potency.Acceptable model fits to all individual subject dose-response data were not achieved for any dermatologic corticosteroid product. However, population dose-responses were adequately described by the Emax model. On the basis of these data, the optimal dose duration used for comparison of multisource dermatologic corticosteroid products is recommended to be equal to the ED50 based on population modeling of pilot dose-response study data." @default.
• W2099494304 created "2016-06-24" @default.
• W2099494304 creator A5001018089 @default.
• W2099494304 creator A5020138765 @default.
• W2099494304 creator A5022473461 @default.
• W2099494304 creator A5042461315 @default.
• W2099494304 creator A5042922415 @default.
• W2099494304 creator A5054747309 @default.
• W2099494304 creator A5058754322 @default.
• W2099494304 date "1999-10-01" @default.
• W2099494304 modified "2023-10-12" @default.
• W2099494304 title "Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling" @default.
• W2099494304 cites W1483964410 @default.
• W2099494304 cites W1987325737 @default.
• W2099494304 cites W1989200125 @default.
• W2099494304 cites W1993608991 @default.
• W2099494304 cites W2006052678 @default.
• W2099494304 cites W2015707706 @default.
• W2099494304 cites W2019429579 @default.
• W2099494304 cites W2025012202 @default.
• W2099494304 cites W2029749394 @default.
• W2099494304 cites W2034266801 @default.
• W2099494304 cites W2076847565 @default.
• W2099494304 cites W2078865702 @default.
• W2099494304 cites W2093611919 @default.
• W2099494304 cites W2110525034 @default.
• W2099494304 cites W2129049338 @default.
• W2099494304 cites W2285506723 @default.
• W2099494304 cites W2407525469 @default.
• W2099494304 cites W294082901 @default.
• W2099494304 cites W298552283 @default.
• W2099494304 cites W2044526175 @default.
• W2099494304 doi "https://doi.org/10.1053/cp.1999.v66.a101209" @default.
• W2099494304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10546918" @default.
• W2099494304 hasPublicationYear "1999" @default.
• W2099494304 type Work @default.
• W2099494304 sameAs 2099494304 @default.
• W2099494304 citedByCount "29" @default.
• W2099494304 countsByYear W20994943042012 @default.
• W2099494304 countsByYear W20994943042013 @default.
• W2099494304 countsByYear W20994943042014 @default.
• W2099494304 countsByYear W20994943042015 @default.
• W2099494304 countsByYear W20994943042016 @default.
• W2099494304 countsByYear W20994943042019 @default.
• W2099494304 countsByYear W20994943042021 @default.
• W2099494304 countsByYear W20994943042022 @default.
• W2099494304 crossrefType "journal-article" @default.
• W2099494304 hasAuthorship W2099494304A5001018089 @default.
• W2099494304 hasAuthorship W2099494304A5020138765 @default.
• W2099494304 hasAuthorship W2099494304A5022473461 @default.
• W2099494304 hasAuthorship W2099494304A5042461315 @default.
• W2099494304 hasAuthorship W2099494304A5042922415 @default.
• W2099494304 hasAuthorship W2099494304A5054747309 @default.
• W2099494304 hasAuthorship W2099494304A5058754322 @default.
• W2099494304 hasConcept C111113717 @default.
• W2099494304 hasConcept C112705442 @default.
• W2099494304 hasConcept C126322002 @default.
• W2099494304 hasConcept C16005928 @default.
• W2099494304 hasConcept C185592680 @default.
• W2099494304 hasConcept C202751555 @default.
• W2099494304 hasConcept C2776804153 @default.
• W2099494304 hasConcept C2908647359 @default.
• W2099494304 hasConcept C42404028 @default.
• W2099494304 hasConcept C55493867 @default.
• W2099494304 hasConcept C57992300 @default.
• W2099494304 hasConcept C71924100 @default.
• W2099494304 hasConcept C98274493 @default.
• W2099494304 hasConcept C99454951 @default.
• W2099494304 hasConceptScore W2099494304C111113717 @default.
• W2099494304 hasConceptScore W2099494304C112705442 @default.
• W2099494304 hasConceptScore W2099494304C126322002 @default.
• W2099494304 hasConceptScore W2099494304C16005928 @default.
• W2099494304 hasConceptScore W2099494304C185592680 @default.
• W2099494304 hasConceptScore W2099494304C202751555 @default.
• W2099494304 hasConceptScore W2099494304C2776804153 @default.
• W2099494304 hasConceptScore W2099494304C2908647359 @default.
• W2099494304 hasConceptScore W2099494304C42404028 @default.
• W2099494304 hasConceptScore W2099494304C55493867 @default.
• W2099494304 hasConceptScore W2099494304C57992300 @default.
• W2099494304 hasConceptScore W2099494304C71924100 @default.
• W2099494304 hasConceptScore W2099494304C98274493 @default.
• W2099494304 hasConceptScore W2099494304C99454951 @default.
• W2099494304 hasIssue "4" @default.
• W2099494304 hasLocation W20994943041 @default.
• W2099494304 hasLocation W20994943042 @default.
• W2099494304 hasOpenAccess W2099494304 @default.
• W2099494304 hasPrimaryLocation W20994943041 @default.
• W2099494304 hasRelatedWork W1987880512 @default.
• W2099494304 hasRelatedWork W2018887812 @default.
• W2099494304 hasRelatedWork W2027745545 @default.
• W2099494304 hasRelatedWork W2041805321 @default.
• W2099494304 hasRelatedWork W2044291706 @default.
• W2099494304 hasRelatedWork W2088148024 @default.
• W2099494304 hasRelatedWork W2165756709 @default.
• W2099494304 hasRelatedWork W2254638634 @default.
• W2099494304 hasRelatedWork W2321603838 @default.
• W2099494304 hasRelatedWork W2369345461 @default.
• W2099494304 hasVolume "66" @default.

• next